This fundamental knowledge is urgently needed in order to select the proper ncRNA markers for early T2DM diagnostics and prognosis, to select novel therapeutic targets, and to identify which ncRNAs are critical for monocyte/macrophage activation under the metabolic conditions that can be controlled by SGLT2 inhibitors or can define the response of patients to SGLT2 inhibitors. Here, SLC5A2 is linked to type 2 diabetes mellitus.